Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

计划入组 50 人 · 首次发布于 2014 年 12 月 1 日

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

计划入组 8 人 · 首次发布于 2023 年 8 月 9 日

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

计划入组 155 人 · 首次发布于 2016 年 10 月 17 日

gp140 targeted antibodies

N332-GT5 gp140

Clade C gp140

Urticaria Emerges as Concern in Phase 1 Trial of HIV mRNA Vaccines

Accelerated Manufacturing Platform Enables Rapid HIV Vaccine Production for Clinical Trials

ImmuPharma Advances P140 Autoimmune Program with Novel Non-Immunosuppressive Mechanism